Pharmaceutical ingredients Korean listed companies
Grouped by the industry code each company registered with DART. Sorted by latest quarterly operating profit.
Companies3
Operating profit₩1.04tnlatest quarter, combined
Operating losses0
Average dividend yield1.0%1 payers
There are 3 KOSPI and KOSDAQ companies classified under pharmaceutical ingredients. Combined operating profit for the latest reported quarter across 3 of them was ₩1.04tn; none posted an operating loss. The largest by quarterly operating profit were Samsung Biologics, Celltrion and Medy-Tox. 1 paid a cash dividend, with an average reported yield of 1.0%.
Pharmaceutical ingredients companies
| Company | Latest quarter op. profit | Dividend yield | Articles 30d | Signals |
|---|---|---|---|---|
| Samsung Biologics KOSPI | ₩586bn +23% YoY | – | 78 | Op. margin 20%+ Supply contract |
| Celltrion KOSPI | ₩452bn +86% YoY | – | 16 | Profit +50% Revenue +30% Revenue & profit growth Op. margin 20%+ |
| Medy-Tox KOSDAQ | ₩4.8bn -25% YoY | 1.0% | 19 | – |
Industry codes are the primary business each company registered with DART and may not reflect its full business mix. Figures come from DART filings; prices are not included. Not investment advice.